Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: OpusX who wrote (1415)	8/24/1999 12:08:00 PM
From: Doug Bean	Respond to of 1837

All; Spoke with IR this morning . He stated that getting an analyst in was being worked on very hard. They have made trips to talk with analysts and hope to have at least one visit soon. he stated very clearly that this was a top priority. Also they are still working on signing a female spokesperson but have nothing concrete yet. They expect a couple of new approvals hopefully in the 3rd quarter,, but you never know when working with the FDA. The now have over 125 salespeople in the field making calls on high prescribing OBGYN doctors and they are getting a very good length of time 12-15 minutes with the doctors ( this is very high). Even with 125+ salespeople it will take a good deal of time on a national basis. Mostly they are still very high on their prospects and still agree with the $100,000,000 sales rate by the 18th month after the approval. Anyway there are a few items coming yet this fall which should help like the bone marker study which should be complete in November, but our real payoff is down the road aways CRDoug